KIF1A

MARCH 2, 2024

Read the Article Rare Roundup The Jackson Laboratory offers “Exploring Rare Disease Through Translational Research” MiniCourse Human health is incredibly complex; developing safe, effective treatments requires knowledge of molecular mechanisms, cell biology, and drug administration.

Laboratories 119

Laboratories Cell Biology Disease Research 119

Drug Target Review

JULY 13, 2023

In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development. Dewpoint Therapeutics, a platform drug discovery company founded in 2018, has been at the forefront of this exciting field.

Disease 98

Disease Small Molecule Cell Biology Drugs 98

The Pharma Data

FEBRUARY 24, 2022

Their findings are published online in Nature Cell Biology. “We are amazed by the efficiency of small-molecule PROTAC in simultaneously targeting EZH2 and cMyc in cancer cells.”

Small Molecule 52

Small Molecule Cell Biology Research Drug Development 52

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 98

Disease Treatment Drugs Clinical Trials 98

Codon

APRIL 9, 2024

Department of Defense administered mefloquine, the synthetic drug developed at Walter Reed in the U.S., only issued “the strongest ‘black box’ warning” against the drug in 2013. Few journal articles were written about the project using her (or anyone’s) name before 2010. Nobody had an answer.

Drugs 138

Drugs Science Research Doctors 138

Drug Target Review

JANUARY 16, 2025

She has a PhD in Microbiology and Cell Biology from the University of Illinois, followed by work in biochemistry as a post-doctoral fellow at UCSF. About the authors Ann E Cleves Ann is VP of Application Science for Optibrium s BioPharmics Division, which focuses on 3D computational modelling for molecular design.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52

Drug Target Review

APRIL 1, 2025

Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders. Co-founder and CEO Dr Dan Williams brings over 20 years of experience in biochemistry and drug development, with a strong background in research and clinical trials.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52